en Cardiology Cardiology Original Article Original Article <span style="font-size:14px;"><span style="font-family:Times New Roman;"><span style="line-height:14pt"><span new="" roman="" times=""><b><i><span style="color:blue">Background</span></i></b><i><span style="color:blue">:</span></i> Cardiovascular disease is the main cause of death among breast cancer survivors. Several chemotherapy drugs may cause cardiovascular toxicity. Our study aimed to assess the late effects of chemotherapy on left ventricular (LV) systolic and diastolic function in a group of female breast cancer survivors.<span style="font-size:9.0pt"></span></span></span><br> <span style="line-height:14pt"><span new="" roman="" times=""><b><i><span style="color:blue">Methods:</span></i></b> Our study was a case-control study consisted of 60 breast cancer survivors who had undergone chemotherapy for more than 5 years and a control group of 49 women without breast cancer. All patients underwent echocardiography and left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), pulse-Doppler early transmitral peak flow velocity (E wave), early diastolic (e&#39;), and left atrial (LA) diameter were calculated.<i><span style="font-size:10.0pt"></span></i></span></span><br> <span style="line-height:14pt"><span new="" roman="" times=""><b><i><span style="color:blue">Results:</span></i></b> The mean LVEF and GLS were reduced in chemotherapy group (51.63&plusmn;7.93% vs. 55.37&plusmn;3.50%, P=0.002 and -17.99&plusmn;3.27% vs. -19.25&plusmn;2.27%, P=0.025). Also, the chemotherapy group had a larger left ventricular end-systolic internal diameter than the control group (1.74&plusmn;0.44cm/m² vs. 1.58&plusmn;0.22cm/m², P= 0.011). Logistic regression analysis showed among the different cardiovascular risk factors, chemotherapy had an association with decreasing LVEF.<b><i><span style="color:blue"></span></i></b></span></span><br> <span style="line-height:14pt"><span new="" roman="" times=""><b><i><span style="color:blue">Conclusion</span></i></b><i><span style="color:blue">:</span></i> Breast cancer survivors might have an excess risk of having subclinical LV dysfunction over time. These findings present the potential benefits of echocardiographic assessment in breast cancer survivors.</span></span></span></span><span style="font-size:12pt"><span style="line-height:14pt"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:10.0pt"><span style="color:#0033cc"></span></span></i></b></span></span></span> cancer, cardiotoxicity, chemotherapy, left ventricular dysfunction, strain 511 518 http://caspjim.com/browse.php?a_code=A-10-1165-2&slc_lang=en&sid=1 Maryam Nabati dr.mr.nabati@gmail.com 100319475328460037539 100319475328460037539 Yes Department of Cardiology, Faculty of Medicine, Mazandaran University of Medical Sciences, Cardiovascular Research Center, Sari, Iran Ghasem Janbabai 100319475328460037540 100319475328460037540 No Department of Hematology, Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran Mohammadreza Najjarpor 100319475328460037541 100319475328460037541 No Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran Jamshid Yazdani 100319475328460037542 100319475328460037542 No Department of Biostatics, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran